Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders

DD Arnold, A Yalamanoglu, O Boyman - Frontiers in immunology, 2022 - frontiersin.org
Background The cytokine interleukin (IL)-1 plays a pivotal role in immune-mediated
disorders, particularly in autoinflammatory diseases. Targeting this cytokine proved to be …

Anakinra therapy for non-cancer inflammatory diseases

G Cavalli, CA Dinarello - Frontiers in pharmacology, 2018 - frontiersin.org
Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-
1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory …

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory …

M Romano, ZS Arici, D Piskin, S Alehashemi… - Annals of the …, 2022 - ard.bmj.com
Background The interleukin-1 (IL-1) mediated systemic autoinflammatory diseases,
including the cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor …

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

CA Dinarello, A Simon… - Nature reviews Drug …, 2012 - nature.com
Abstract Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain
thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory …

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

E Ozaki, M Campbell, SL Doyle - Journal of inflammation research, 2015 - Taylor & Francis
The inflammasome is a molecular platform formed by activation of an innate immune pattern
recognition receptor seed, such as NLRP3. Once activated, NLRP3 recruits the adapter ASC …

Treating inflammation by blocking interleukin-1 in humans

CA Dinarello, JWM van der Meer - Seminars in immunology, 2013 - Elsevier
IL-1 is a master cytokine of local and systemic inflammation. With the availability of specific
IL-1 targeting therapies, a broadening list of diseases has revealed the pathologic role of IL …

[HTML][HTML] Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

N Ruperto, HI Brunner, P Quartier… - … England Journal of …, 2012 - Mass Medical Soc
Background Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic
arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human …

A clinical perspective of IL‐1β as the gatekeeper of inflammation

CA Dinarello - European journal of immunology, 2011 - Wiley Online Library
An expanding spectrum of acute and chronic non‐infectious inflammatory diseases is
uniquely responsive to IL‐1β neutralization. IL‐1β‐mediated diseases are often called “auto …

Recommendations for the management of autoinflammatory diseases

NM Ter Haar, M Oswald, J Jeyaratnam… - Annals of the …, 2015 - ard.bmj.com
Autoinflammatory diseases are characterised by fever and systemic inflammation, with
potentially serious complications. Owing to the rarity of these diseases, evidence-based …

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

N Ter Haar, H Lachmann, S Özen, P Woo… - Annals of the …, 2013 - ard.bmj.com
Objective To evaluate the response to treatment of autoinflammatory diseases from an
international registry and an up-to-date literature review. Methods The response to treatment …